Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes

Leukemia Research

Volumn 22, Issue SUPPL. 1, 1998, Pages

  Cheson, Bruce D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 Azacytidine; Cytarabine; Myelodysplastic syndromes; Toporecan

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLACINOMYCIN; AZACITIDINE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; HOMOHARRINGTONINE; HYDROXYUREA; TIOGUANINE;

CELL DIFFERENTIATION; CLINICAL TRIAL; CONFERENCE PAPER; DNA METHYLATION; HUMAN; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SOCIAL SUPPORT; SURVIVAL;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HARRINGTONINES; HUMANS; MYELODYSPLASTIC SYNDROMES; PYRIMIDINES; TOPOTECAN;

EID: 0031816074     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00039-3     Document Type: Conference Paper

References (49)

1. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986;4:1857-64.
2. Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol 1987;14(suppl 1):126-33.
3. Ellison RR, Holland JF, Weil M, Jacquillat C, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507-23.
4. Baccarani M, Tura S. Differentiation of myeloid leukaemic cells: new possibilities for therapy. Br J Haematol 1979;42:485-90.
5. Baccarani M, Zaccaria A, Bandini G, Cavazzini G, Fanin R, Tura S. Low-dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. Leuk Res 1983;7:539-45.
6. Griffin JD, Spriggs D, Wisch JS, Kufe DW. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol 1985;3:982-91.
7. Hoelzer D, Ganser A, Schneider W, Heimpel H. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes. Semin Oncol 1985;12(suppl 3):208-11.
8. Inbal A, Januszewicz E, Rabinowictz M, Shaklai M. A therapeutic trial with low-dose cytarabine in myelodysplastic syndromes and acute leukemia. Acta Haematol 1985;73:71-4.
9. Jehn U, De Bock R, Haanen C. Clinical trial of low-dose ara-C in the treatment of acute leukemia and myelodysplasia. Blut 1984;48:255-61.
10. Maiolo AT, Foa P, Cortellaro M, et al. Low-dose cytosine arabinoside (ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 1987;72:61-5.
11. Powell BL, Capizzi RL, Jackson DV, et al. Low-dose ara-C for patients with myelodysplastic syndromes. Leukemia 1988;2:153-6.
12. Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985;56:1001-5.
13. Tricot G, De Bock R, Dekker AW, et al. Low-dose cytosine arabinoside (ara-C) in myelodysplastic syndromes. Br J Haematol 1984;58:231-340.
14. Vincent PC, Buck M, Young GAR, Benson WJ. Low-dose cytarabine in acute non-lymphoblastic leukemia or myelodysplastic syndrome: report of six cases of review of the literature. Aust NZ J Med; 1985;15:10-5.
15. Winter JN, Variakojis D, Gaynor ER, Larson RA, Miller KB. Low-dose cytosine arabinoside (ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer 1985;56:443-9.
16. Wisch JS, Griffin JD, Kufe DW. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 1983;309:1599-602.
17. Degos L, Castaigne S, Tilly H, Sigaux F, Daniel MT. Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin Oncol 1985;12(suppl 3):196-9.
18. Letendre L, Levitt R, Pierre RV, et al. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Hematol 1995;48:233-6.
19. Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989;64:1812-8.
20. Najean Y, Pecking A. Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Cancer 1989;44:1976-82.
21. Miller KB, Kyungmann K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1989;65:162-8.
22. De Bock R, Van Hoof A, Van Hove W, et al. Oral idarubicin (IDA) for RAEB, RAEBt, and acute leukemia (AL) postmyelodysplastic syndrome (MDS): a Phase II open study (abstr 794). Proc ASCO 1989;8:204.
23. Shibuya T, Teshima T, Harada M, et al. Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin. Leuk Res 1990;14:161-7.
24. Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M. Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 1988;80:1095-103.
25. Kantarjian HM, Beran M, Ellis A, et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993;81:1146-51.
26. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-6.
27. Feldman E, Sullivan P, Ahmed T, Mittelman A, Puccio C, Arlin Z. Phase II trial of homoharringtonine (HHT) in patients with myelodysplastic syndromes (MDS) (abstr 701). Blood 1988;72(Suppl 1):198a.
28. Rowinsky EK, Adjei A, Donehower RC, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994;12:2193-203.
29. Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88:2473-9.
30. Beran M, O'Brien S, Estey E, Keating M, Kantarjian H. Topotecan, a topoisomerase I inhibitor, induces complete remissions in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (abstr 2308). Blood 1996;88(Suppl 1):580a.
31. Beran M, Kantarjian H, Keating M, et al. Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (abstr 2593). Blood 1997;90(Suppl 1):583a.
32. Vogler WR, Miller DS, Keller JW. 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood 1976;48:331-7.
33. Saiki JH, McCredie KB, Vietti TJ, et al. 5-Azacytidine in acute leukemia. Cancer 1978;42:2111-4.
34. Saiki JH, Bodey GP, Hewlett JS, et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group study. Cancer 1981;47:1739-42.
35. Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacytidine: 10 years later. Cancer Treat Rep 1987;71:737-46.
36. Larson RA, Sweet DL, Golomb HM, Testa JR, Rowley JD. Response to 5-azacytidine in patients with refractory acute non-lymphocytic leukemia and association with chromosome findings. Cancer 1982;49:2222-5.
37. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous-infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 1991;37:100-4.
38. Silverman LR, Davis RB, Holland JF, et al. 5-Azacytidine (AZ) as a low-dose continuous infusion is an effective therapy for patients with myelodysplastic syndromes (MDS) (abstr 768). Proc ASCO 1989;8:198.
39. Silverman LR, Holland JF, Nelson D, et al. Trilineage (TLR) response of myelodysplastic syndromes (MDS) to subcutaneous (SQ) azacytidine (Aza C) (abstr 747). Proc ASCO 1991;10:222.
40. Silverman LR. A randomized comparison of 5-azacytidine and supportive care in patients with myelodysplastic syndrome (MDS). Proc ASCO 1998;17:14a (Abstract 53).
41. Wijermans PW, Krulder JWM, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11(Suppl 1):19-23.
42. Doll D, Sun PCJ, List AF. Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis. Leuk Res 1994;18:381-4.
43. Oscier DG, Worsley A, Hamblin TJ, Mufti GJ. Treatment of chronic myelomonocytic leukaemia with low-dose etoposide. Br J Haematol 1989;72:468-71.
44. Wattel E, Guerci A, Hecquest B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood 1996;88:2480-7.
45. Zervas J, Geary CG, Oleesky S. Sideroblastic anemia treated with immunosuppressive therapy. Blood 1974;44:117-23.
46. Martinez JA, Martin G, Sanz GF, et al. A phase II clinical trial of carboplatin infusion in high-risk acute non-lymphocytic leukemia. J Clin Oncol 1991;9:39-43.
47. Tamura K, Makino S, Araki Y. A phase I study of a new cisplatin derivative for hematologic malignancies. Cancer 1990;66:2059-63.
48. Meyers FJ, Welborn J, Lewis J, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989;7:173-8.
49. Spitzer TR, Lazarus HM, Crum ED, Weissman R. Treatment of myelodysplastic syndromes with low-dose oral 6-thioguanine. Med Pediat Oncol 1988;16:17-20.